| Issue Date | Title | Author(s) |
| 2016 | Changes in adipokines in newly diagnosed type 2 diabetes patients treated with exenatide, insulin or pioglitazone | Yang, Xubin; Xu, Wen; Zhu, Dalong; Sun Zilin; Guo, Lixin; Yang, Tao; Wu, Ge; Shi, Lixin; Li, Qifu; Qiu, Lin; Li, Qiang; Guo, Xiaohui; Luo, Zuojie; Lu, Juming; Shan, Zhongyan; Yang, Wenying; Ji, Qiuhe; Yan, Li; Li, Hong; Yu, Xuefeng; Li, Shaoqing; Zhou, Zhiguang; Lv, Xiaofeng; Liang, Zhen; Lin, Shaoda; Zeng, Longyi; Yan, Jinhua; Ji, Linong; Weng, Jianping |
| 2016 | Changes in adipokines in newly diagnosed type 2 diabetes patients treated with exenatide, insulin or pioglitazone | Yang, Xubin; Xu, Wen; Zhu, Dalong; Sun Zilin; Guo, Lixin; Yang, Tao; Wu, Ge; Shi, Lixin; Li, Qifu; Qiu, Lin; Li, Qiang; Guo, Xiaohui; Luo, Zuojie; Lu, Juming; Shan, Zhongyan; Yang, Wenying; Ji, Qiuhe; Yan, Li; Li, Hong; Yu, Xuefeng; Li, Shaoqing; Zhou, Zhiguang; Lv, Xiaofeng; Liang, Zhen; Lin, Shaoda; Zeng, Longyi; Yan, Jinhua; Ji, Linong; Weng, Jianping |
| 2019 | Direct medical costs for patients with type 2 diabetes in 16 tertiary hospitals in urban China: A multicenter prospective cohort study | Li, Xiang; Xu, Zhangrong; Ji, Linong; Guo, Lixin; Liu, Jing; Feng, Kun; Xu, Yushan; Zhu, Dalong; Jia, Weiping; Ran, XinWu; Chen, Limin; Zhao, Shi; Shi, Bingying; Zhu, Jun; Shan, Zhongyan; Zhou, Zhiguang; Zeng, Longyi; Weng, Jianping; Ren, Qian; Zhou, Yan; Wei, Suhong; Zhao, Lingfei; Liu, Yanjun; Niu, Wenfang; Jiang, Yan; Tong, Guoyu; Hou, Xuhong; Huang, Hui; Chang, Baocheng; Yi, Lan; Liu, Xingjun; Xiao, Shan; Wang, Chuyuan; Zhang, Yang; Lu, Jing |
| 2018 | Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study | Zhu, Dalong; Gan, Shenglian; Liu, Yu; Ma, Jianhua; Dong, Xiaolin; Song, Weihong; Zeng, Jiao'e; Wang, Guixia; Zhao, Wenjuan; Zhang, Qiu; Li, Yukun; Fang, Hui; Lv, Xiaofeng; Shi, Yongquan; Tian, Haoming; Ji, Linong; Gao, Xin; Zhang, Lihui; Bao, Yuqian; Lei, Minxiang; Li, Ling; Zeng, Longyi; Li, Xiaoying; Hou, Xinghua; Zhao, Yu; Hu, Tianxin; Ge, Xiaoyun; Zhao, Guiyu; Li, Yongguo; Zhang, Yi; Chen, Li |
| 2017 | Efficacy and safety of metformin and sitagliptin based triple antihyperglycemic therapy (STRATEGY): a multicenter, randomized, controlled, non-inferiority clinical trial | Xu, Wen; Mu, Yiming; Zhao, Jiajun; Zhu, Dalong; Ji, Qiuhe; Zhou, Zhiguang; Yao, Bin; Mao, Anhua; Engel, Samuel S.; Zhao, Bin; Bi, Yan; Zeng, Longyi; Ran, Xingwu; Lu, Juming; Ji, Linong; Yang, Wenying; Jia, Weiping; Weng, Jianping |
| 2019 | Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease | Yan, Jinhua; Yao, Bin; Kuang, Hongyu; Yang, Xubin; Huang, Qin; Hong, Tianpei; Li, Yushu; Dou, Jingtao; Yang, Wenying; Qin, Guijun; Yuan, Huijuan; Xiao, Xinhua; Luo, Sihui; Shan, Zhongyan; Deng, Hongrong; Tan, Ying; Xu, Fen; Xu, Wen; Zeng, Longyi; Kang, Zhuang; Weng, Jianping |
| Jan-2020 | Observational study evaluating the effectiveness of physician-targeted education for improving glycemic management of patients with type 2 diabetes (BEYOND II) | Weng, Jianping; Zhao, Jiajun; Zhou, Zhiguang; Guo, Xiaohui; Zou, Dajin; Ji, Qiuhe; Tong, Nanwei; Li, Qifu; Zhu, Jun; Li, Qiang; Qin, Guijun; Feng, Ping; Yang, Liyong; Gao, Zhengnan; Chen, Lulu; Li, Hong; Li, Yiming; Zeng, Longyi; Zhu, Dalong; Lu, Juming; Luo, Tianhong; Cui, Nan |
| 2017 | Pharmacodynamic subgroup analysis of glucose kinase activator (GKA) after 12 weeks of treatment with HMS5552 in T2DM patients in China | Zhu, Dalong; Gan, Shenglian; Liu, Yu; Ma, Jianhua; Dong, Xiaolin; Song, Weihong; Zeng, Jiaoe; Wang, Guixia; Zhao, Wenjuan; Zhang, Qiu; Li, Yukun; Fang, Hui; Lv, Xiaofeng; Shi, Yongquan; Tian, Haoming; Ji, Linong; Gao, Xin; Zhang, Lihui; Bao, Yuqian; Lei, Minxiang; Li, Ling; Zeng, Longyi; Li, Xiaoying; Hu, Tianxin; Zhao, Guiyu; Ge, Xiaoyun; Zhao, Yu; Hou, Xinghua; Li, Yongguo; Zhang, Yi; Chen, Li |
| 2017 | Pharmacodynamic subgroup analysis of glucose kinase activator (GKA) after 12 weeks of treatment with HMS5552 in T2DM patients in China | Zhu, Dalong; Gan, Shenglian; Liu, Yu; Ma, Jianhua; Dong, Xiaolin; Song, Weihong; Zeng, Jiaoe; Wang, Guixia; Zhao, Wenjuan; Zhang, Qiu; Li, Yukun; Fang, Hui; Lv, Xiaofeng; Shi, Yongquan; Tian, Haoming; Ji, Linong; Gao, Xin; Zhang, Lihui; Bao, Yuqian; Lei, Minxiang; Li, Ling; Zeng, Longyi; Li, Xiaoying; Hu, Tianxin; Zhao, Guiyu; Ge, Xiaoyun; Zhao, Yu; Hou, Xinghua; Li, Yongguo; Zhang, Yi; Chen, Li |
